tag:blogger.com,1999:blog-4241416962008169508.post3706746730004843853..comments2024-03-29T06:40:19.495-04:00Comments on Just A Life Sciences Blog...: Merck's 2003 Medco Deal: Interesting (If Mistaken) "Short-Sighted" Divestiture ThesisUnknownnoreply@blogger.comBlogger2125tag:blogger.com,1999:blog-4241416962008169508.post-70690621786337122472012-01-29T12:22:02.986-05:002012-01-29T12:22:02.986-05:00I just flat out missed it -- thanks Marilyn!
I...I just flat out missed it -- thanks Marilyn!<br /><br />I'll post on it -- crediting you -- later today.<br /><br />Again, thanks a ton!<br /><br />NamasteCondorhttp://shearlingsplowed.blogspot.comnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-62361854683876366092012-01-28T21:35:53.052-05:002012-01-28T21:35:53.052-05:00This has nothing to do with this post, but I was s...This has nothing to do with this post, but I was surprised that you didn't blog on the FDA's decision to turn down Merck's request for a new chronic kidney disease indication for Vytorin and for Zetia when prescribed with simvastatin.<br /><br />The FDA did permit a revision to the Vytorin label (on pp. 27-28 of the label) that states the results of the SHARP trial, but without an indication Merck won't be able to advertise the use of Vytorin for reducing the risk of cardiac events in CKD.Marilyn Mannhttp://marilynmann.wordpress.comnoreply@blogger.com